Valuation: Transgene

Market Cap 194M 217M 181M 164M 309M 20.96B 311M 2.17B 848M 10.66B 814M 796M 34.27B P/E 2026 *
-5.05x
P/E 2027 * -3.21x
Enterprise Value 124M 139M 116M 105M 199M 13.47B 200M 1.4B 545M 6.85B 523M 512M 22.03B EV / Sales 2026 *
17.3x
EV / Sales 2027 * 25.8x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Transgene

1 day-5.88%
3 months-5.88%
6 months-20.00%
Current year-20.00%
Current year 0.8
Extreme 0.8
0.85
1 year 0.8
Extreme 0.8
1.08
3 years 0.7
Extreme 0.7
1.59
5 years 0.01
Extreme 0.0101
3.06
10 years 0.01
Extreme 0.0101
4.26
Manager TitleAgeSince
Chief Executive Officer 65 31/05/2023
Director of Finance/CFO - 26/03/2024
Chief Tech/Sci/R&D Officer - 01/04/2025
Director TitleAgeSince
Director/Board Member 61 26/07/2010
Director/Board Member 77 18/06/2013
Director/Board Member 88 31/12/2006
Change 5-day change 1-year change 3-year change Capi.($)
-5.88%-.--% - - 225M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.34% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
+0.50%-2.14%+331.33%+702.20% 42.84B
-0.72%-3.99%+28.50%+29.94% 42.79B
+0.34%-0.52%+6.56%+109.35% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
-0.50%-3.10%-10.19%-14.35% 24.05B
Average -0.36%-0.25%+53.35%+123.79% 43.81B
Weighted average by Cap. +0.69%-0.50%+56.27%+130.20%

Financials

2026 *2027 *
Net sales 7.2M 8.06M 6.72M 6.1M 11.49M 780M 11.58M 80.72M 31.54M 396M 30.25M 29.6M 1.27B 7.2M 8.06M 6.72M 6.1M 11.49M 780M 11.58M 80.72M 31.54M 396M 30.25M 29.6M 1.27B
Net income -38.2M -42.75M -35.64M -32.37M -60.97M -4.14B -61.42M -428M -167M -2.1B -161M -157M -6.76B -61.6M -68.94M -57.47M -52.2M -98.32M -6.67B -99.05M -691M -270M -3.39B -259M -253M -10.9B
Net Debt -69.2M -77.45M -64.56M -58.64M -110M -7.49B -111M -776M -303M -3.81B -291M -284M -12.25B -7.7M -8.62M -7.18M -6.53M -12.29M -834M -12.38M -86.33M -33.73M -424M -32.35M -31.65M -1.36B
Projected Income Statement - Annual - Transgene
Logo Transgene
Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.
Employees
152
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7070EUR
Average target price
1.100EUR
Spread / Average Target
+55.59%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Transgene